A. Screen for Par-4 secretagogues. MEFs were treated with 25 M amounts of generic compounds or vehicle (V) control for 24 h. The CM and whole-cell lysates were subjected to Western blot analysis with the indicated antibodies. Collagen1A1 (Col1A1) was used as a loading control for protein secretion, as it was generally unchanged in response to the treatments. The samples were also subjected to SDS-PAGE and Coomassie blue staining for albumin levels in serum from the CM, which was another loading control. Actin served as a loading control for the lysates. ) were transiently co-transfected with p53-reporter (PG13-luc containing p53 binding sites), mutant reporter (MG15-luc containing mutated binding sites for p53) or pGL3 control luc construct, and -galactosidase expression construct. The transfectants were treated with CQ (25 M) or vehicle for 24 h, luciferase activity was determined and normalized to corresponding -galactosidase activity and expressed as relative luciferase activity units. CQ induced luciferase activity from the p53-reporter luciferase construct but not from a luciferase construct containing mutant response element in p53 +/+ MEFs. By contrast, CQ failed to induce luciferase activity in p53 -/-MEFs.
B. CQ induced upregulation of p53-responsive genes. C57BL/6 mice were injected once daily with CQ (25 mg/kg body weight) or vehicle for five consecutive days. Blood samples were collected from the mice on the sixth day, and plasma was examined for expression of p53, p21, PIG3, Par-4, and actin by Western blot analysis. 
C. CQ did not elevate

Supplemental Methods
Primers used for Real-Time quantitative reverse transcription PCR (qRT-PCR) assay
The primers used were: mRab8a Forward: 5'-CTGGCACTCGACTATGGGAT-3'; mRab8a Reverse: 5'-TTTGCTTTGATATCCCTGGC-3'; mRab8b Forward: 5'-CACGCCTCTTCAGATGTTGA-3'; mRab8b Reverse: 5'-CGACTTTGCACTTGTCTCCA-3'; mouse Par-4 Forward: 5'-AGAATGAAGCTGCGACCCTC-3'; mouse Par-4 Reverse: 5'-ATCTTCTGGGGC ACTGGTTG-3'; and internal control primers for mGAPDH Forward:
5'-GTGAGGCAAAAGGGAAGGTG-3'; mGAPDH Reverse: 5'-AGGCATGGCAGATTCAG AGT-3'.
Chromatin-Immunoprecipitation (ChIP) Assay
ChIP assays for CQ-induced or vehicle-treated basal levels of p53 binding to the Rab8b promoter or to Par-4 gene involved treatment of wild type MEFs (2 x10 6 cells) with vehicle or CQ (25 uM) for 8-12 Hrs. ChIP analysis was performed by using the ChIP Assay kit from Millipore or Active Motif according to the instructions provided by the manufacturer. Sheared chromatin was immunoprecipitated with antibodies using mouse IgG (sc-2025, Santa Cruz Biotechnology), or anti-p53 antibody (1C12 mouse monoclonal antibody #2524 from Cell Signaling. DNA fragments were amplified by using validated primers for p53 binding site on the Rab8b promoter from EpiTect ChIP qPCR primer assay for mouse Rab8b (GPM1054933(-)01A; Qiagen) and resolved on agarose gels, or quantitative PCR was performed on CFX96 Touch™ Real-Time PCR Detection System (Bio-Rad). Two different primer sets: (1) Forward 5' TCACCTGAGCAAAACGACGA 3'; Reverse 5' GCGATCAGAGCTAAGGGGAC 3'; (2) Forward 5' GGCTGAGCCTGTCCTCTTTC 3'; Reverse 5' GTGCTGTGTTGGTTTCTCGG 3'; were used along the Par-4 gene, which does not contain a p53-binding site. GAPDH control primers used were: Forward 5'-ATG GTT GCC ACT GGG GAT CT-3'; Reverse 5'-TGC CAA AGC CTA GGG GAA GA-3'.
Animal experiments
To determine whether CQ induced Par-4 secretion in immunocompetent mice, C57BL/6 mice were injected via the intraperitoneal (i.p.) route with a single injection of CQ (50 mg/kg body weight) or vehicle, and whole-blood samples were collected 24 h later. Plasma was separated from the blood samples, heated at 56 o C to inactivate complement. Aliquots of the mouse plasma samples were added to the growth medium (final 20% mouse plasma) of normal and cancer cells in culture and tested for induction of ex vivo apoptosis in cancer cells. To test the effect of CQ on metastatic growth of tumors, EO771 cells or LLC1 cells expressing luciferase (0.5 x 10 6 cells) were injected via the tail vein in Par-4 +/+ (wild type) or Par-4 -/-C57BL/6 mice and 24 h later, the mice were injected i.p. with CQ (25 mg/kg body weight) injection given daily for five consecutive days. Each group included 8 mice. Plasma from the mice was examined 24 h after the 5th CQ injection for Par-4 expression. The mice were imaged for luciferase expression as previously described (Zhao et al., 2011) , and humanely killed to examine their tumors at day 21. The lungs were then perfused, stained with India ink and the tumor nodules were scored as previously described (Zhao et al., 2011) .
To test whether Par-4 secretion induced by CQ was involved in inhibition of LLC1-or EO771-derived metastatic tumor growth, we used an experimental metastasis model. Athymic (nu/nu) mice were injected i.v. with 500 x 10 5 LLC1 cells, and 24 h later injected i.p. with CQ (25 mg/kg body weight) or vehicle once every day for 5 consecutive days. Animals injected with CQ were also injected within 2 h with either the control IgG or Par-4 polyclonal antibody (20 g/injection). Each group included 10 mice. After 21 days, the lungs were perfused, stained with India ink and the tumor nodules were scored.
To determine whether CQ inhibits the growth of large bulky tumors, we injected 4 x 10 5 H460 or LLC1 cells subcutaneously in nude (nu/nu) mice to generate tumors in the flanks. When the tumors had grown to ca. 200 mm 3 volume (indicated by arrow), the mice (10 per group) were injected with CQ (25 mg/kg body weight) or vehicle once daily throughout the experiment, and tumor growth was measured with calipers over period of the experiment to calculate tumor volume. All animal procedures were performed with University of Kentucky IACUC approval.
